Journal article icon

Journal article

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.

Abstract:

Objectives
To investigate the safety of ofatumumab retreatment in rheumatoid arthritis.

Methods
Patients with active rheumatoid arthritis participating in two phase III trials (OFA110635 and OFA110634) and a phase II extension trial (OFA111752) received individualised open-label ofatumumab retreatment (700 mg X 2 intravenous infusions two weeks apart) ≥24 weeks following the first course and ≥16 weeks following further courses. Retreatment required evidence of clinical ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1371/journal.pone.0157961

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Kennedy Institute for Rheumatology
Role:
Author
Expand authors...
GlaxoSmithKline Pharmaceuticals More from this funder
Publisher:
Public Library of Science Publisher's website
Journal:
PLoS One Journal website
Volume:
11
Issue:
6
Pages:
320-330
Publication date:
2016-06-23
Acceptance date:
2016-06-05
DOI:
EISSN:
1932-6203
ISSN:
1932-6203
Source identifiers:
656055
Keywords:
Pubs id:
pubs:656055
UUID:
uuid:b767952c-880b-49f3-8dc3-5c8caea843fa
Local pid:
pubs:656055
Deposit date:
2016-11-01

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP